Sexually Transmitted Diseases Clinical Trial
Official title:
A Phase 2, Double-Blind, Placebo-Controlled Study to Determine the Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects With External Genital Warts
This is a Phase 2, double-blind, placebo-controlled study to determine the dose regimen, safety, tolerability, and efficacy of VP-102 in subjects with External Genital Warts (EGW). This study is divided into two parts (Part A and Part B). Increasing durations of skin exposure to study drug (VP-102 or placebo) will be evaluated in three treatment groups prior to progressing to enrollment in Part B. Part A & B will enroll a approximately 108 subjects completing 4 treatment applications every 21 days and continuing with follow-up assessments at Day 84, 112 and 147.
This study is to determine the Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts. It is divided into two parts (Part A and Part B). The aim of Part A is to determine the two best treatment regimens for evaluation of safety and efficacy in Part B.In Part A, Study drug (VP-102 or placebo) will be administered once every 21 days for up to four applications. Enrollment will begin in Group 1, then proceed into Group 2, and lastly into Group 3. A safety review will be conducted to determine whether enrollment can be initiated into the next Group. An additional blinded safety review will be performed after all six subjects in Group 3 have completed the 48-hour Visit, in order to support dose selection for Part B (Safety and Efficacy). Part B of the study will begin enrollment only after the Sponsor has selected the two dose regimens from Part A. The study will remain blinded until completion of both parts of the study. In Part A, up to 18 subjects will be randomized to VP-102 or placebo treatment with three different regimens. When Part B is open an additional ~90 subjects will be enrolled and randomized to VP-102 or placebo with two treatment regimens. Two of the treatment arms will be VP-102 Regimen 1 and VP-102 Regimen 2. The other two treatment arms will be placebo (Placebo Regimen 1 and Placebo Regimen 2), with corresponding durations of skin exposure matching those selected for VP-102 Regimen 1 and Regimen 2. As an example, if the regimens selected from Part A are the 2-hour and 6-hour applications of VP-102, then VP-102 Regimen 1 would be VP-102 treatment for 2-hours and VP-102 Regimen 2 would be VP-102 treatment for 6-hours. Likewise, Placebo Regimen 1 would be placebo treatment for 2 hours and Placebo Regimen 2 would be placebo treatment for 6-hours. Randomization of the four treatment arms (VP-102 Regimen 1:VP-102 Regimen 2:Placebo Regimen 1:Placebo Regimen 2) will be 3:3:2:2. In both Regimen 1 and Regimen 2, study drug will be administered to EGW once every 21 days for up to four applications. Subjects will be asked to remove the study drug at the designated time selected from the dose regimen findings in Part A of the study. Treatment will continue with a minimum of every 21 days, until complete clearance or a maximum of four treatment sessions. Safety assessments including recording of local skin reactions are conducted at each treatment visit and at follow up visits Day 84, 112, and 147. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02579135 -
Reducing HIV Risk Among Adolescents: Evaluating Project HEART
|
N/A | |
Enrolling by invitation |
NCT06127277 -
Next4You: A Fully Mobile Relationships Based Program for Youth in Foster Care
|
N/A | |
Recruiting |
NCT05889689 -
Evaluation of an Adolescent Pregnancy Prevention Program; Relationship Smarts+ With Lessons From Mind Matters
|
N/A | |
Completed |
NCT02516930 -
A Non-inferiority Randomized Controlled Trial to Evaluate Promoting Condom Use Among MSM and Transgender Individuals in China
|
N/A | |
Completed |
NCT03063385 -
Puerto Rico Cuidalos Parent-adolescent Program
|
N/A | |
Completed |
NCT01411878 -
Louisville Teen Pregnancy Prevention Project
|
N/A | |
Completed |
NCT02009046 -
Randomized Evaluation of a Multi-Component, Rights-Based Sexuality Education Initiative for High School Students
|
N/A | |
Completed |
NCT01303575 -
Internet-Based Sexual Health Education for Middle School Native American Youth
|
N/A | |
Completed |
NCT00167505 -
All About Youth: Evaluation of Sexual Risk Avoidance and Risk Reduction Programs for Middle School Students
|
N/A | |
Completed |
NCT00183456 -
A Peer-Oriented HIV Prevention Outreach Program for Individuals at High Risk for HIV and Other STIs
|
Phase 2 | |
Completed |
NCT00336180 -
Adolescent Drug and HIV Prevention in South Africa
|
Phase 2/Phase 3 | |
Completed |
NCT01084395 -
Reducing HIV Risk Among Mexican Youth
|
N/A | |
Completed |
NCT00161382 -
Development and Evaluation of an HIV, STD, and Pregnancy Prevention Program for Middle School Students
|
N/A | |
Completed |
NCT00710060 -
Effectiveness of a Community-level HIV/STD Prevention Intervention in Promoting Safer Sexual Behaviors in High-risk Populations
|
Phase 3 | |
Completed |
NCT00640653 -
Efficacy of an Abstinence-Only HIV Risk-Reduction Intervention for Young African-American Adolescents
|
N/A | |
Completed |
NCT00289939 -
Reducing HIV & Domestic Violence Risk in Women Offenders
|
Phase 3 | |
Completed |
NCT00137943 -
Parents Matter!: Interventions to Promote Effective Parent-Child Communication
|
Phase 1 | |
Completed |
NCT03408743 -
Engineering an Online STI Prevention Program: CSE2
|
N/A | |
Completed |
NCT06104813 -
Evaluation of Deaf Men's Knowledge About Sexual Health
|
||
Not yet recruiting |
NCT05910580 -
Improving Alcohol and Substance Use Care Access, Outcome, Equity During the Reproductive Years
|
N/A |